Q-omics provides the consensus-scored HNRNPA1P21 profile across patient tissues and cancer cell-line models. HNRNPA1P21 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, HNRNPA1P21 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, HNRNPA1P21 RNA expression shows 15,465 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, and UVM as cancer lineages where HNRNPA1P21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HNRNPA1P21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HNRNPA1P21 survival associations across molecular data types. HNRNPA1P21 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HNRNPA1P21 RNA expression–survival associations across cancer types. High HNRNPA1P21 expression shows unfavorable associations in UVM and KICH, but favorable associations in HNSC, SKCM, CESC and BLCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for HNRNPA1P21 RNA expression.
This table summarizes HNRNPA1P21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HNRNPA1P21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HNRNPA1P21 shows higher tumor expression in HNSC, KIRC, COAD, STAD, LUAD and LIHC. The HNSC box plot shows higher HNRNPA1P21 RNA expression in tumor versus normal tissue (log2 FC = +1.541, t-test p < 0.001).
This table shows molecular features associated with HNRNPA1P21 in patient tissues and cancer cell lines. In patient samples, HNRNPA1P21 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
